Kilitch Drugs announces 1:1 bonus shares, Q3 results

Revenue declinedResults View source PDF Explain this filing

KILITCH · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-8.6%Reaction day

₹181.50

prior close

₹180.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.5%-8.1% vs market

Pharmaceuticals peers, median of 157sector-0.6%-8.0% vs sector

On the reaction day the stock moved 8.1 pts less than Nifty Microcap 250 and 8.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-3.1

10m

-1.8

15m

-2.5

30m

-3.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-8.6-0.5-8.1-0.6-8.0

Next day

-9.9-2.0-7.9-1.4-8.5

-12.1-2.7-9.4-2.1-10.0

-11.3-1.7-9.6-1.6-9.7

-8.8-1.4-7.4-1.6-7.2

-12.5-2.8-9.7-2.4-10.1

-10.5-2.8-7.6-2.9-7.6

15d

-11.6-8.4-3.2-6.3-5.2

-9.7-9.1-0.6-6.5-3.2

-31.6-4.0-27.5-3.3-28.2

-19.0+2.6-21.6+0.9-19.9

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Kilitch Drugs board approved 1:1 bonus issue (1 free share per 1 held) on Feb 11, 2026, subject to shareholder approval at EGM on March 13. Bonus from free reserves of about Rs 17.48 cr, credited by April 10, 2026. Q3 FY26 standalone net sales rose to Rs 44.67 cr from Rs 16.51 cr YoY, but 9-month standalone revenue fell to Rs 116.6 cr from Rs 125.3 cr. 9M PAT slipped to Rs 18.4 cr from Rs 19.8 cr. Authorized capital to rise from Rs 25 cr to Rs 40 cr.

Likely market impact

Bonus is positive for shareholders, but the 9-month revenue and profit decline is a concern.